Surmodics将2025财年调整后的每股收益指导从$（0.62）-$（0.42）上调至$（0.35）-$（0.20）vs $（0.55）Est;将2025财年销售指导从$1.14亿-$1.17亿提高至1.165亿-118.5亿美元vs 115.686亿美元Est

Fiscal Year 2025 Financial Guidance

Surmodics is increasing its fiscal 2025 total revenue to a range of $116.5 million to $118.5 million, representing a decrease of 8% to 6% compared to fiscal 2024. Excluding SurVeil DCB license fee revenue,(1) Surmodics now expects fiscal 2025 total revenue to range from $115.0 million to $117.0 million, representing a decrease of 5% to 3% compared to fiscal 2024 . The company's prior guidance called for fiscal 2025 total revenue of $114 to $117 million, representing a decrease of 10% to 7% compared to fiscal 2024, and total revenue excluding SurVeil DCB license fee revenue(1)of $112.5 million to $115.5 million, representing a decrease of 7% to 5% compared to fiscal 2024.

As previously disclosed, the company expects fiscal 2025 financial performance to remain impacted by lower SurVeil DCB license fee and product revenue. Given the completion of the TRANSCEND pivotal clinical trial in the second quarter of fiscal 2025, the company continues to expect SurVeil DCB license fee revenue to decrease by $3.6 million in fiscal 2025, with no further recognition of SurVeil DCB license fee revenue subsequent to March 31, 2025. The company expects SurVeil DCB product revenue to decrease by approximately $7.5 million in fiscal 2025, driven primarily by lower demand for commercial shipments from Abbott, the Company's exclusive distribution partner for the product.

The company now expects fiscal 2025 GAAP net loss to range from $(1.70) to $(1.55) per diluted share. The company's prior guidance called for fiscal 2025 GAAP net loss to range from $(1.60) to $(1.40) per diluted share. Fiscal 2025 Non-GAAP net loss(4) is increased to range from $(0.35) to $(0.20) per diluted share. The company's prior guidance called for fiscal 2025 Non-GAAP net loss(4) of $(0.62) to $(0.42) per diluted share.

The company's GAAP and non-GAAP net loss per diluted share guidance assumes approximately $16.0 million of merger-related charges in fiscal 2025, compared to $3.7 million in fiscal 2024.

Surmodics' fiscal 2025 financial guidance does not reflect possible tariff impacts. The company's tariff exposure related to its supply chain, including raw materials, components and products sourced outside represents a modest percentage of its total product sales. The company's tariff exposure related to sales by its customers of medical devices and diagnostic test kits, which utilize Surmodics' chemical components and medical device coatings, on which Surmodics generates product and royalty revenue, is difficult to quantify as Surmodics' has customers who manufacture their products in the U.S. and abroad and sell or distribute those products in the U.S. and abroad. International trade actions announced, threatened or implemented by the U.S. or other countries, and uncertainty related to such trade actions and our customers response to these actions are unpredictable.